Maze Therapeutics, Inc. (MAZE) Price & Analysis

Compare

54 Followers

MAZE Stock Chart & Stats

$29.26

Market closed

$29.26

Day’s Range― - ―

52-Week Range$6.71 - $29.76

Previous CloseN/A

VolumeN/A

Average Volume (3M)703.38K

Market Cap

$1.25B

Enterprise Value$298.52M

Total Cash (Recent Filing)$264.54M

Total Debt (Recent Filing)$25.01M

Price to Earnings (P/E)―

Beta0.97

Next EarningsN/A

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding43,850,883

10 Day Avg. Volume395,167

30 Day Avg. Volume703,383

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.24

Enterprise Value/Revenue119.41

Enterprise Value/Gross Profit646.14

Enterprise Value/Ebitda-2.40

Forecast

1Y Price Target

$34.83

Price Target Upside19.04% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering7

Bulls Say, Bears Say

Bulls Say

Market PotentialAnalyst's probability of success for MZE782 has increased to 70% in PKU and 65% in CKD, resulting in a higher price target for the stock.

Regulatory PathThe validation of proteinuria and slope as surrogate endpoints would de-risk Maze’s regulatory path and potentially shorten timelines to approval.

Therapy PositioningMaze’s MZE829 is uniquely positioned as the leading APOL1 targeted therapy, directly aligned with the recent PARASOL initiative and Rosenberg et al.’s validation of proteinuria and slope as predictors of kidney failure.

Bears Say

Market AdoptionSafety differentiation of MZE782 is now considered an added value driver as efficacy alone is not enough for market adoption.

Market CompetitionThe scarcity value for MZE782 in the CKD indication is recognized due to the lack of other SLC6A19 inhibitors currently in clinical development.

Regulatory ChallengesThe data suggests that while efficacy is necessary, safety will be the decisive factor in determining whether MZE782 can play a clinically and commercially meaningful role.

Maze Therapeutics, Inc. News

Maze Therapeutics files to sell 9.23M shares of common stock for holders

16:17 EDT Maze Therapeutics (MAZE) files to sell 9.23M shares of common stock for holders Published first on...

18h ago

MAZE

Maze Therapeutics appoints Herve Hoppenot as chairman of the board

Maze Therapeutics (MAZE) announced the appointment of Herve Hoppenot as Chairman of its Board of Directors, succeeding Charles...

12d ago

INCY

MAZE

Maze Therapeutics Appoints Hervé Hoppenot as Chairman

An update from Maze Therapeutics, Inc. ( ($MAZE) ) is now available. On October 3, 2025, Maze Therapeutics,...

12d ago

MAZE

Two new option listings on September 17th

New option listings for September 17th include Maze Therapeutics Inc (MAZE) and WhiteFiber Inc (WYFI). Published first on...

1M ago

MAZE

WYFI

Maze Therapeutics price target raised to $34 from $19 at Guggenheim

Guggenheim analyst Debjit Chattopadhyay raised the firm’s price target on Maze Therapeutics (MAZE) to $34 from $19 and...

1M ago

MAZE

Maze Therapeutics price target raised to $50 from $34 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Maze Therapeutics (MAZE) to $50 from $34 and keeps a...

1M ago

MAZE

Maze Therapeutics Advances Clinical Programs Amid Financial Stability

Maze Therapeutics, Inc. ( ($MAZE) ) has released its Q2 earnings. Here is a breakdown of the information...

1M ago

MAZE

Maze Therapeutics price target raised to $37 from $30 at BTIG

BTIG raised the firm’s price target on Maze Therapeutics (MAZE) to $37 from $30 and keeps a Buy...

1M ago

MAZE

Maze Therapeutics price target raised to $34 from $28 at Leerink

Leerink analyst Joseph Schwartz raised the firm’s price target on Maze Therapeutics (MAZE) to $34 from $28 and...

1M ago

MAZE

Kroger reports mixed Q2, U.S. CPI rises 0.4% in August: Morning Buzz

The major averages were broadly higher near noon following U.S. CPI data that could potentially influence the Federal...

1M ago

CNC

Maze Therapeutics Secures $150M in Private Placement

Maze Therapeutics, Inc. ( ($MAZE) ) has provided an update. On September 10, 2025, Maze Therapeutics entered into...

1M ago

MAZE

Maze Therapeutics announces results from Phase 1 trial of MZE782

Maze Therapeutics (MAZE) announced positive clinical results from the Phase 1 healthy volunteer study of MZE782, an oral...

1M ago

MAZE

Maze Therapeutics prices 4M shares at $16.25 in private placement

Maze Therapeutics (MAZE) entered into a securities purchase agreement for an oversubscribed private placement of its securities for...

1M ago

MAZE

Maze Therapeutics Appoints Misbah Tahir as CFO

Maze Therapeutics, Inc. ( ($MAZE) ) has shared an update. On September 2, 2025, Maze Therapeutics, Inc. announced...

2M ago

MAZE

MAZE FAQ

What was Maze Therapeutics, Inc.’s price range in the past 12 months?

Maze Therapeutics, Inc. lowest stock price was $6.71 and its highest was $29.76 in the past 12 months.

What is Maze Therapeutics, Inc.’s market cap?

Maze Therapeutics, Inc.’s market cap is $1.25B.

When is Maze Therapeutics, Inc.’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were Maze Therapeutics, Inc.’s earnings last quarter?

Currently, no data Available

Is Maze Therapeutics, Inc. overvalued?

According to Wall Street analysts Maze Therapeutics, Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Maze Therapeutics, Inc. pay dividends?

Maze Therapeutics, Inc. does not currently pay dividends.

What is Maze Therapeutics, Inc.’s EPS estimate?

Maze Therapeutics, Inc.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Maze Therapeutics, Inc. have?

Maze Therapeutics, Inc. has 43,850,883 shares outstanding.

What happened to Maze Therapeutics, Inc.’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Maze Therapeutics, Inc.?

Currently, no hedge funds are holding shares in MAZE

Maze Therapeutics, Inc. Stock Smart Score

Neutral

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

236.40%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Maze Therapeutics, Inc.

Maze Therapeutics, Inc. (MAZE) is a biotechnology company focused on translating genetic insights into novel therapeutic approaches for treating a range of diseases. Operating within the biotechnology and pharmaceutical sectors, Maze leverages its proprietary COMPASS platform to identify and validate genetic modifiers, which are then developed into potential therapeutic products. The company's core focus is on discovering genetic pathways that can be modulated to treat diseases with significant unmet medical needs.

Maze Therapeutics, Inc. (MAZE) Earnings & Revenues

Historic Earnings Reports

MAZE Stock 12 Month Forecast

Average Price Target

$34.83

▲(19.04% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"8":"$8","51":"$51","18.75":"$18.75","29.5":"$29.5","40.25":"$40.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":50,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$50.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":34.83,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$34.83</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":17,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$17.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[8,18.75,29.5,40.25,51],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2025","6":"Apr<br/>2025","9":"Jul<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,25.81,27.67076923076923,29.53153846153846,31.392307692307693,33.253076923076925,35.113846153846154,36.97461538461538,38.83538461538461,40.69615384615385,42.55692307692308,44.417692307692306,46.27846153846154,48.13923076923077,{"y":50,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,25.81,26.50384615384615,27.197692307692307,27.89153846153846,28.585384615384612,29.279230769230768,29.97307692307692,30.666923076923077,31.36076923076923,32.05461538461538,32.748461538461534,33.44230769230769,34.136153846153846,{"y":34.83,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,25.81,25.13230769230769,24.454615384615384,23.776923076923076,23.09923076923077,22.42153846153846,21.743846153846153,21.066153846153846,20.388461538461538,19.71076923076923,19.033076923076923,18.355384615384615,17.677692307692308,{"y":17,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":15,"date":1730419200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":15,"date":1733011200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":15,"date":1735689600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":15,"date":1738368000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":15,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.23,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.9,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.59,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.1,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.66,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.9,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.32,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.81,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >